

## **<sup>18</sup>FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients**

### **SUPPLEMENTARY MATERIALS**

**Supplementary Table 1: Gene expression analysis: primers and MGB probes**

<b>Gene Name</b>	<b>Id</b>	<b>Forward Primer</b>	<b>Reverse Primer</b>	<b>Probe</b>	<b>Amplicon size (bp)</b>	<b>exon</b>
KPNA2	NM_002266.2	CTCTAGGAAACATTGCAGGTGATG	AGTGGGTCAACTGCACCGTACT	AGTGTCCGAGACTTGGTTA	73	5-6
MYBL2	NM_002466.2	GACAGCAGGACTGGAAGTTCCT	ATTCAAACTCTCAGCCACCTGTA	TAACCGCACTGACCAGCAATGCCA	86	3-4
CDC2 (CDK1)	NM_001786.4		Hs04177802_m1		109	3-4
CDC20	NM_001255.2		0426680_mH		115	10-11